EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
EQRx announced promising results from pivotal Phase 3 studies of sugemalimab, an anti-PD-L1 antibody, in non-small cell lung cancer (NSCLC). The GEMSTONE-301 study showed a significant improvement in progression-free survival (PFS) for patients with Stage III NSCLC receiving sugemalimab as consolidation therapy, with a median PFS of 9.0 months vs. 5.8 months for placebo (HR=0.64). The GEMSTONE-302 study indicated that sugemalimab combined with chemotherapy provided a median PFS of 9.0 months vs. 4.9 months for placebo (HR=0.48). Both studies were published in The Lancet Oncology.
- GEMSTONE-301 demonstrated a median PFS of 9.0 months vs. 5.8 months for placebo (HR=0.64, p=0.0026).
- GEMSTONE-302 indicated a median PFS of 9.0 months vs. 4.9 months for placebo (HR=0.48, p<0.0001).
- Both trials showed sugemalimab was well-tolerated with no new safety signals.
- Overall survival data remain immature for both studies, indicating uncertainty around long-term benefits.
Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy
Concurrently published results from the pivotal Phase 3 GEMSTONE-302 study demonstrated PFS benefit with sugemalimab plus chemotherapy in first-line systemic treatment of patients with Stage IV NSCLC, regardless of tumor pathologic subtype or PD-L1 expression levels
Data reinforce the potential of sugemalimab for the treatment of this broad range of patients with NSCLC
CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX) a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology. The publications were accompanied by a comment article.
In GEMSTONE-301, sugemalimab resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo when administered as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy. This represents the first positive Phase 3 data for an anti-PD-L1 agent in this broader population of patients with Stage III NSCLC.1
In GEMSTONE-302, the addition of sugemalimab to standard-of-care chemotherapy as first-line systemic treatment provided a statistically significant, clinically meaningful improvement in PFS in patients with Stage IV NSCLC, regardless of PD-L1 expression levels or pathologic subtype of NSCLC.2
“Taken together, the publication of data from these two Phase 3 studies in The Lancet Oncology adds to a growing body of evidence suggesting that sugemalimab may be a promising option for a wide range of patients with Stage III or Stage IV non-small cell lung cancer upon approval in global regions beyond China,” said Vince Miller, MD, physician-in-chief at EQRx. “We look forward to progressing discussions with global regulatory authorities with the goal of bringing a new, high-quality treatment option to these patient populations at a much lower price.”
Results from GEMSTONE-301 reported in The Lancet Oncology are as follows:
- Sugemalimab as consolidation therapy demonstrated a statistically significant and clinically meaningful improvement in PFS vs. placebo, as assessed by blinded independent central review (BICR) at a prespecified interim analysis.
- Median PFS was 9.0 months vs. 5.8 months (Hazard Ratio [HR]=0.64, p=0.0026).
- Clinical benefit was observed in patients who received either concurrent or sequential chemoradiotherapy prior to treatment with sugemalimab compared to placebo.
- For patients who received prior concurrent chemoradiotherapy (cCRT), median PFS was 10.5 months vs. 6.4 months (HR=0.66).
- For patients who received prior sequential chemoradiotherapy (sCRT), median PFS was 8.1 months vs. 4.1 months (HR=0.59).
- Overall survival (OS) data were immature at the time of the analysis, but an encouraging trend for a survival benefit with sugemalimab vs. placebo was observed, with follow-up of patients ongoing.
- Sugemalimab was generally well-tolerated, with no new safety signals observed.
- In the sugemalimab group,
9% of patients (n=22/255) experienced grade 3 or 4 treatment-emergent adverse events (TEAEs) related to study treatment. - In the placebo group,
6% (7/126) experienced grade 3 or 4 TEAEs related to study treatment.
- In the sugemalimab group,
Results of the final PFS analysis from GEMSTONE-302, also reported in The Lancet Oncology, are as follows:
- Sugemalimab plus platinum-based chemotherapy significantly prolonged PFS (median 9.0 vs 4.9 months; HR=0.48; p<0.0001) compared with placebo plus platinum-based chemotherapy.
- OS data were immature at the time of the final PFS analysis, but preliminary median OS was 22.8 months in the sugemalimab plus chemotherapy arm compared to 17.7 months in the placebo plus chemotherapy arm (HR=0.67).
- Clinical benefit was observed across all subgroups, regardless of PD-L1 expression level or pathologic subtype of NSCLC.
- Sugemalimab was generally well-tolerated, with no new safety signals observed.
53.8% of patients (172/320) in the sugemalimab group and56.0% (89/159) in the placebo group experienced treatment-related grade 3 or 4 TEAEs, with the most common events for both groups being neutrophil count decrease, white blood cell count decrease, anemia, platelet count decrease and neutropenia.
EQRx’s partner, CStone Pharmaceuticals, previously presented results on the use of sugemalimab in the treatment of patients with Stage III and Stage IV NSCLC at ESMO 20213,4 and the IASLC 2021 World Conference on Lung Cancer, respectively.5,6
Sugemalimab is being studied in patients with different stages of NSCLC, in patients with gastric and esophageal cancers and in patients with lymphoma.
About Lung Cancer
Every 15 seconds, a person across the world is diagnosed with lung cancer, and every 18 seconds, a person dies of the disease, making it the second most commonly diagnosed cancer and leading cause of cancer deaths worldwide. In 2020, an estimated 2.2 million people were diagnosed with lung cancer.7 NSCLC is the most common type of lung cancer, accounting for
About GEMSTONE-301
GEMSTONE-301 (NCT03728556) is a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of sugemalimab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy. The study was conducted in China by CStone Pharmaceuticals and included 381 patients, who were randomized to the sugemalimab group (n=255) or the placebo group (n=126). The primary endpoint of the trial was progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to RECIST v1.1. Secondary endpoints include OS and PFS as assessed by the investigators and safety. In May 2021, EQRx and CStone Pharmaceuticals announced that GEMSTONE-301 met its primary endpoint of prolonged PFS.
About GEMSTONE-302
GEMSTONE-302 (NCT03789604) is a randomized, double-blind, Phase 3 study designed to evaluate the efficacy and safety of sugemalimab or placebo in combination with carboplatin-based chemotherapy as a first-line treatment in patients with Stage IV squamous or non-squamous NSCLC. The study was conducted in China by CStone Pharmaceuticals and included 479 patients, who were randomized to either the sugemalimab group (n=320) or the placebo group (n=159). The primary endpoint was investigator-assessed PFS. Secondary endpoints include blinded independent central review (BICR)-assessed PFS, safety and OS. CStone Pharmaceuticals previously shared positive results of the final analysis of PFS, the primary endpoint of the study, from GEMSTONE-302 at the IASLC 2021 World Conference on Lung Cancer.9,10
About Sugemalimab
Sugemalimab is an investigational monoclonal antibody targeting programmed death-ligand 1 (PD-L1) discovered by CStone Pharmaceuticals. Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat® transgenic animal platform, which can generate fully human antibodies in one stop. Currently, sugemalimab is being investigated in a number of ongoing clinical trials including one Phase 2 registration study in relapsed/refractory extranodal natural killer (NK)/T cell lymphoma (ENKTL) and four Phase 3 registration studies in Stage III NSCLC (GEMSTONE-301), Stage IV NSCLC (GEMSTONE-302), gastric cancer, and esophageal cancer. Both the GEMSTONE-301 and GEMSTONE-302 studies met their primary endpoints of prolonged PFS, and results were recently presented at global medical congresses. In December 2021, the National Medical Products Administration (NMPA) of China approved the New Drug Application (NDA) for sugemalimab combined with chemotherapy for the first-line treatment of metastatic squamous and non-squamous NSCLC patients. In September 2021, the NDA for Stage III NSCLC was accepted by the NMPA. EQRx holds the development and commercialization rights to sugemalimab outside of Greater China. EQRx and CStone Pharmaceuticals have partnered to expand global access to sugemalimab, with plans to continue regulatory discussions in multiple countries.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may be identified by the use of words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “design,” “strategy,” “future,” “opportunity,” “continue,” “aim,” “plan,” “may,” “look forward,” “should,” “will,” “would,” “will be,” “will likely result,” and similar expressions. These forward-looking statements include, but are not limited to, express or implied statements regarding EQRx’s ability to develop and deliver innovative medicines at radically lower prices, EQRx’s ability to expand its pipeline, plans and timelines for the clinical development of EQRx’s product candidates, including the therapeutic potential, clinical benefits and tolerability thereof, expectations regarding EQRx’s existing collaboration with CStone Pharmaceuticals, as well as other statements regarding plans and market opportunities of EQRx. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to changes in the competitive and highly regulated industries in which EQRx operates, variations in operating performance across competitors, changes in laws and regulations affecting EQRx’s business, delay of any current and future clinical trials or the development of sugemalimab or EQRx’s other drug candidates, the risk that the results of prior clinical trials may not be predictive of future results in connection with future clinical trials, EQRx’s ability to successfully demonstrate the safety and efficacy of its drug candidates, the timing and outcome of EQRx’s planned interactions with regulatory authorities; obtaining, maintaining and protecting its intellectual property, EQRx’s relationships with CStone Pharmaceuticals and its other existing and future collaboration partners and EQRx’s ability to maintain its existing license and other collaboration agreements, risks associated with EQRx’s ability to otherwise implement its business plans, including risks associated with its growth strategy, obtaining regulatory approvals, and creating a global payer network, and other risks associated with its plans to create a new kind of pharmaceutical company, the risk of downturns and a changing regulatory landscape in the highly competitive healthcare and biopharmaceutical industries, the size and growth of the markets in which EQRx operates and its ability to offer innovative medicines at reduced prices, and EQRx’s ability to operate as a public company. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the prospectus dated December 23, 2021 and filed with the SEC under Rule 424(b) and other documents filed by EQRx from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and EQRx assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
References
1 Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim analysis of a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. Published January 14, 2022. DOI: https://doi.org/10.1016/S1470-2045(21)00630-6.
2 Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): an interim and final analyses of a double-blind, randomised, phase 3 clinical trial. The Lancet Oncology. Published January 14, 2022. DOI: https://doi.org/10.1016/S1470-2045(21)00650-1.
3 EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021. Press Release. September 17, 2021. Available here: https://www.eqrx.com/press-release/eqrx-announces-presentation-of-phase-3-data-demonstrating-a-progression-free-survival-benefit-with-sugemalimab-consolidation-therapy-in-patients-with-stage-iii-nsclc-at-esmo-congress-2021/. Accessed January 14, 2021.
4 Wu YL, Zhou Q, Chen M, et al. LBA43 - GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT). ESMO 2021. Annals of Oncology (2021) 32 (suppl_5): 32, S1321. 10.1016/annonc/annonc741.
5 EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC. Press Release. September 13, 2021. Available here: https://www.eqrx.com/press-release/eqrx-announces-presentation-of-updated-data-from-pivotal-phase-3-study-of-anti-pd-l1-antibody-sugemalimab-in-combination-with-chemotherapy-as-a-first-line-treatment-for-stage-iv-nsclc/. Accessed January 14, 2021.
6 Zhou C, Wang Z, Sun Y, et al. MA13.07 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC. Journal of Thoracic Oncology 2021; 16(10): S926-S7. DOI:10.1016/j.jtho.2021.08.180.
7 World Health Organization, International Agency for Research on Cancer. Globocan 2020: Lung Cancer. International Agency for Research on Cancer. Available here: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed January 14, 2021.
8 American Cancer Society, Key Statistics for Lung Cancer. Available here: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed January 14, 2021
9 EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC. Press Release. September 13, 2021. Available here: https://www.eqrx.com/press-release/eqrx-announces-presentation-of-updated-data-from-pivotal-phase-3-study-of-anti-pd-l1-antibody-sugemalimab-in-combination-with-chemotherapy-as-a-first-line-treatment-for-stage-iv-nsclc/
10 Zhou C, Wang Z, Sun Y, et al. GEMSTONE-302: Randomized, Double-Blind, Phase 3 Study of Sugemalimab or Placebo Plus Platinum-Based Chemotherapy as First-Line Treatment for Metastatic NSCLC. IASLC 2021 World Conference on Lung Cancer. MA13.07 Mon Sept 13. DOI: https://doi.org/10.1016/j.jtho.2021.08.180.
FAQ
What were the results of the GEMSTONE-301 study for EQRX's sugemalimab?
What does the GEMSTONE-302 study reveal about sugemalimab?
How does sugemalimab impact patients with Stage III NSCLC?
When were the results of the Phase 3 studies published?
